Vardenafil in the multidisciplinary management of erectile dysfunction: a narrative review on multidimensional outcomes and clinical integration - Takeaways - MDSpire

Vardenafil in the multidisciplinary management of erectile dysfunction: a narrative review on multidimensional outcomes and clinical integration

  • By

  • Jiedong Zhou

  • Shian Hu

  • Yong Ouyang

  • Yucheng Kong

  • Min Liu

  • April 13, 2026

  • 0 min

Share

  • 1

    Erectile dysfunction (ED) affects 30-40% of men over 40 and over 50% of those over 70, often indicating broader health issues.

  • 2

    Vardenafil, a PDE5 inhibitor, offers rapid onset and minimal food interactions, making it a viable first-line treatment for ED.

  • 3

    Multidisciplinary approaches to ED treatment, involving various specialists, improve outcomes by addressing physiological and psychological factors.

  • 4

    Combination therapies using vardenafil show greater improvements in erectile function and quality of life compared to monotherapy.

  • 5

    Vardenafil's unique pharmacological properties, including higher selectivity for PDE5, may provide advantages over other PDE5 inhibitors for specific ED subgroups.

Original Source(s)

Vardenafil in the multidisciplinary management of erectile dysfunction: a narrative review on multidimensional outcomes and clinical integration

  • by Jiedong Zhou, Shian Hu, Yong Ouyang, Yucheng Kong, Min Liu

  • April 13, 2026

Related Content

A gender-based investigation of risk factors for infectious complications after percutaneous nephrolithotomy for kidney stones: insight for personalized management

The Oral Microbiome's Role: Linking Periodontal Dysbiosis to Systemic Health Issues

Urinary continence outcomes, surgical margin status, and complications after radical prostatectomy in 2,141 German patients treated in one high-volume inpatient rehabilitation clinic in 2022